MyOIT App Study

Study Objective: The goal of this study is to evaluate the effectiveness of a mobile application in supporting oral immunotherapy (OIT) management. MyOIT is designed to assist users with daily dosing and symptom tracking in a simple and efficient way. Users can log their OIT doses and track their progress over time.

Who is Eligible: Individuals currently undergoing oral immunotherapy (OIT) for a food allergen are eligible to participate. Participants must have access to an iPhone running iOS 17 or later and be at least 12 months of age. 

Study Duration: 12 Months

Study Principle Investigator: Dr. Sayantiani Sindher

View the Full Flyer HERE

Contact for more information and to
schedule a screening visit:
Clinic Email: snpcenterallergy.inquiry@stanford.edu
Clinic Phone: (650) 521-7237

For complaints, concerns, or participant's rights, 
contact 1-866-680-2906.

EISI – Early Food Introduction & Allergy Prevention

Research Study Opportunity for New Parents!

• We are studying educational methods for infant feedings to prevent food allergies 
• Criteria: Parent or caregiver of an infant 4 - 11 months of age willing to enroll in a clinical trial for 6 months

View the Full Flyer HERE

Contact for more information and to
schedule a screening visit:
Clinic Email: snpcenterallergy.inquiry@stanford.edu
Clinic Phone: (650) 521-7237

For complaints, concerns, or participant's rights, 
contact 1-866-680-2906.

ASTRO – Allergen-Specific Treatment Responses to Omalizumab

Study Objective: To understand the role of Omalizumab in food allergy treatment. We aim to identify what biologic markers can help predict patient success during Omalizumab monotherapy treatment by analyzing blood and tissue samples and the results of clinical allergy tests.

Who is Eligible: Participants (1-55 years of age) with 1 or more food allergies diagnosed by their healthcare provider. Participants must be starting Omalizumab therapy prescribed by their healthcare provider. Our clinicians will further determine the participant's eligibility based on the participant's medical history and other criteria in the clinic. Consent is required prior to enrollment.

Study Duration: 12 months (minimum 3 visits)

Study Principal Investigators: Sayantani B. Sindher, MD

Study Sponsor: Sean N. Parker Center for Allergy and Asthma Research. 

Compensation for participation is provided.

View the Full Flyer HERE

Contact for more information and to
schedule a screening visit:
Clinic Email: snpcenterallergy.inquiry@stanford.edu
Clinic Phone: (650) 521-7237

For complaints, concerns, or participant's rights, 
contact 1-866-680-2906.

PRESTIGE Study

RPT904 (Ozureprubart) Food Allergy Study

Study Objective: To understand the efficacy of RPT904 (Ozureprubart), a long-acting monoclonal antibody, as a potential treatment for IgE-mediated food allergies such as peanut, milk, egg, cashew, or walnut. RPT904 has the potential to be dosed every 8 to 12 weeks, compared to every 2 or 4 weeks for competitors.

Who is Eligible: Participants 12 to 55 years of age with a confirmed IgE-mediated food allergy to at least one of the following: peanut, milk, egg, cashew, or walnut. Participant eligibility criteria will be confirmed as part of the screening process through skin prick test, IgE, and food challenge results.

Those with uncontrolled asthma, severe eczema, or a history of severe anaphylaxis requiring intubation are not eligible.

Study Duration: Approximately 68 to 72 weeks (about 18 months), including screening, two 24-week treatment periods, and a follow-up phase. Participants will receive subcutaneous injections every 8 or 12 weeks, along with food challenge assessments and laboratory visits.

Study Principal Investigators: Sayantani B. Sindher, MD

Study Sponsor: RAPT Therapeutics, Inc.

Compensation for participation is provided.

View the Full Flyer HERE.

Contact for more information and to schedule a screening visit: Clinic Email: snpcenterallergy.inquiry@stanford.edu

Clinic Phone: (650) 521-7237

For complaints, concerns, or participant's rights, contact 1-877-992-4724.

COMFORT Toddlers Study

DBV712 (Viaskin® Peanut Patch) Food Allergy Study

Study Objective: To understand the safety of DBV712 (Viaskin® Peanut Patch) 250mcg, a epicutaneous immunotherapy, or EPIT, as a potential treatment for IgE-mediated food allergies designed to deliver microgram amounts of allergens to the immune system through intact skin.

Who is Eligible: Children (1-3 years of age) are welcome. Participants must have a peanut allergy diagnosis or be suspected of having a peanut allergy, which will be confirmed by skin prick testing, IgE, and screening food challenge results. Additionally, our physicians will further determine eligibility based on the participant's medical history and other criteria in the clinic.

Those with uncontrolled asthma, severe skin diseases involving the proposed application area (interscapular region), a history of immunotherapy for peanut allergy, or a history of severe anaphylaxis are not eligible.

Study Duration: Taking part in the study involves up to 14 visits to the study site and 8 phone calls. The study lasts from 6 to 24 months and includes a screening period of up to 6 weeks to see if your child is well matched to the study. Toddlers who qualify will be selected at random (like the toss of a coin) to wear either the study active patch or a placebo patch, which looks like the study patch but has no active ingredients, during the first 6 months in the study. During the study you will apply a patch on your child’s back and change the patch every day and keep track of any skin reaction, while keeping your child on a peanut-free diet.

After 6 months, you may continue in the optional extension of the study, in which all participants will receive the active study patch for an additional 18 months. Two weeks after the last patch was used, you will have a follow-up phone call with the study team.

Study Principal Investigator: Sayantani B. Sindher, MD

Study Sponsor: DBV Technologies

Compensation for participation is provided.

View the Full Flyer HERE.

Contact for more information and to schedule a screening visit: Clinic Email: snpcenterallergy.inquiry@stanford.edu

Clinic Phone: (650) 521-7237

For complaints, concerns, or participant's rights, contact:
1-877-992-4724.

Participate in Prescreening at the Sean N. Parker Center for Allergy & Asthma at Stanford University

Condition: Allergies, Food Allergies, Asthma, Eczema, Atopic Dermatitis, Allergic Rhinitis, Eosinophilic Esophagitis (EOE)

Age Group: 0-90 y/o

Duration: 1 Time Event

Description: We invite people with doctor-diagnosed food allergies, asthma, eczema, allergic rhinitis, eosinophilic esophagitis (EOE), and other allergic conditions to participate in prescreening for allergy and asthma research at our center.

Contact: If you are interested in learning more about the study or scheduling a prescreening visit, you can call us at (650) 521-7237 or contact us at snpcenterallergy.inquiry@stanford.edu

SHINGLES Study

Study Objective: This study aims to learn how the body's immune system responds to the shingles vaccine (Shingrix*) in adults aged 50 and older. By collecting blood samples and health information from a wearable device, we hope to understand how the vaccine protects people and how immune responses may differ between individuals.

Who is Eligible: Any adults aged 50 and older who are generally healthy and have not previously received a shingles vaccine may be eligible and are welcome participate. Our physicians will determine the participant's eligibility by reviewing each participant's medical history, current medications, and overall health to ensure they are generally healthy and not immunocompromised.

Study Duration: About 6-8 months, depending on the spacing between the two vaccine doses (2-6months apart). Up to 10 clinic visits.

Study Principal Investigator: Sharon Chinthrajah, MD

Study Sponsor: NIH| Compensation for participation is provided. You will be paid $25 per visit plus $20 for each blood draw, payable at the completion of the study.

Contact for more information and to schedule a pre-screening visit: Clinic Email: snpcenterallergy.inquiry@stanford.edu

Clinic Phone: (650) 521-7237

For complaints, concerns, or participant's right questions, contact: 1-866-680-2906

This study is now closed.

SEAL

SEAL (Stopping Eczema and ALlergy) Study
Study ongoing but no longer recruiting

Study Objective: To test if proactive use of topical skin creams is more effective than common atopic dermatitis (eczema) treatment methods at preventing eczema and food allergies.

Who is Eligible: Any child up to 12 weeks of age is welcomed. Our physicians will determine the participant's eligibility based on the participant's skin and other criteria in the clinic. Parental consent is required prior to enrollment.

Study Duration: 36 months (4 clinic visits)

Study Principal Investigators: Sayantani B. Sindher, MD

Study Sponsor: Stanford University School of Medicine 
Compensation for participation is provided.

Contact for more information and to schedule a pre-screening visit:

Clinic Email:
snpcenterallergy.inquiry@stanford.edu
Clinic Phone: (650) 521-7237

This study is now closed.